Assessment of Cardioversion Using Transesophageal Echocardiography II (ACUTE II)
NCT ID: NCT00289042
Last Updated: 2007-01-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
200 participants
INTERVENTIONAL
1999-12-31
2004-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
HYPOTHESIS: Early cardioversion from atrial fibrillation can be safely performed using a short-term anticoagulation strategy of low molecular weight heparin (Lovenox, Sanofi-Aventis) compared to unfractionated heparin, accompanied by a TEE examination prior to cardioversion. The use of LMWH with TEE will result in a safe, cost-effective, and possible efficacious approach to cardioversion of atrial fibrillation compared to UFH with TEE.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Enoxaparin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with atrial flutter with a documented history (electrocardiography) of atrial fibrillation
* Males and females 18 years of age or older
* Patients have available results of routine clinical labs for standard clinical chemistry and complete blood count within the previous 14 days
Exclusion Criteria
* Use of IV heparin for more than 72 hours immediately prior to randomization.
* Patients with contraindications to TEE, such as dysphagia, or esophageal strictures.
* Patients who will need anticoagulation discontinued because of elective intervening procedure, such as cardiac catheterization or surgery.
* Patients with contraindications to warfarin or heparin
* Patients who require concomitant therapy during the study period with any drug known to affect coagulation or platelet function (i.e. ASA, NSAID, antiplatelet drugs)
* Women of childbearing potential, unless pregnancy can be excluded by medical history incompatible with pregnancy or by serum or urine beta HCG levels.
* Patients who are hemodynamically unstable and thus may require immediate cardioversion.
* Weight less than 40 kg (88 pounds) or more than 125 kg (275 pounds)
* History of gastrointestinal bleeding disorder and/or endoscopically verified ulcer disease within the last year
* History of intracranial or retinal bleeding, or other known disorders with an increased risk of bleeding
* Ischemic stroke in the previous three months
* Uncontrolled hypertension (systolic blood pressure greater than 180 mm Hg or diastolic blood pressure greater than 100 mm Hg)
* Malignancy currently under active treatment, including melanoma
* Patients with renal insufficiency (creatinine \> 2.0 mg/dL) or are renal transplant subjects
* Patients with anemia (Hgb less than 10 gm/dL)
* Patients with thrombocytopenia (platelet count less than 100 x 10\^9/L)
* Positive fecal hemoglobin test
* Life expectancy of less than 6 months
* History of drug and/or alcohol abuse within the last two years
* Patients unable or unwilling to give informed consent
* Patients unable or unwilling to return for follow-up
* Prisoners or wards of the state
* Patients with psychological problems that may decrease compliance with the protocol
* Not willing to complete the Quality of Life Questionnaires x 3
* Participating in another clinical trial and/or taking an investigational medication in the past 30 days
* Patient language, learning skills, or home environment unconducive to self-management
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi
INDUSTRY
The Cleveland Clinic
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Allan L. Klein, MD
Role: PRINCIPAL_INVESTIGATOR
The Cleveland Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cleveland Clinic
Cleveland, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW, Davidoff R, Erbel R, Halperin JL, Orsinelli DA, Porter TR, Stoddard MF; Assessment of Cardioversion Using Transesophageal Echocardiography Investigators. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001 May 10;344(19):1411-20. doi: 10.1056/NEJM200105103441901.
Murray RD, Deitcher SR, Shah A, Jasper SE, Bashir M, Grimm RA, Klein AL. Potential clinical efficacy and cost benefit of a transesophageal echocardiography-guided low-molecular-weight heparin (enoxaparin) approach to antithrombotic therapy in patients undergoing immediate cardioversion from atrial fibrillation. J Am Soc Echocardiogr. 2001 Mar;14(3):200-8. doi: 10.1067/mje.2001.109505.
Murray RD, Shah A, Jasper SE, Goodman A, Deitcher SR, Katz WE, Malouf JF, Stoddard MF, Grimm RA, Klein AL; ACUTE II pilot study. Transesophageal echocardiography guided enoxaparin antithrombotic strategy for cardioversion of atrial fibrillation: the ACUTE II pilot study. Am Heart J. 2000 Jun;139(6):E1-7. doi: 10.1067/mhj.2000.106628.
Elliott DJ, Zhao L, Jasper SE, Lieber EA, Klein AL, Weintraub WS. Health status outcomes after cardioversion for atrial fibrillation: results from the Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) II Trial. Am Heart J. 2008 Aug;156(2):374.e1-6. doi: 10.1016/j.ahj.2008.05.008.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB 2879
Identifier Type: -
Identifier Source: org_study_id